Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Ltd Live Price Chart
Oxygenta Pharmaceutical Ltd Technicals
| 20 Day | ₹ 58.449 |
| 50 Day | ₹ 58.772 |
| 100 Day | ₹ 63.580 |
| 200 Day | ₹ 69.455 |
| 20 Day | ₹ 57.958 |
| 50 Day | ₹ 57.411 |
| 100 Day | ₹ 60.818 |
| 200 Day | ₹ 79.279 |
Oxygenta Pharmaceutical Ltd Performance
| Previous Close | ₹ 58.64 |
| High | ₹ 58.51 |
| Volume | 1011 |
| 52W Range | ₹ 51.31 - ₹ 133.5 |
| Open | ₹ 58.5 |
| Low | ₹ 57.5 |
| Market Cap | ₹ 220 Cr |
Oxygenta Pharmaceutical Ltd Fundamentals
| ROCE | -53.257 |
| P/E Ratio | -11.990 |
| P/B Ratio | 0.000 |
| Industry P/E | 0.000 |
| Debt to Equity | 39.407 |
| ROE | 46.669 |
| EPS | -4.880 |
| Dividend Yield | 0.000 |
| Book Value | -9.918 |
| Face Value | 10.000 |
Oxygenta Pharmaceutical Ltd Financials
| Particulars | Y202503 | Y202403 | Y202303 | Y202203 | Y202103 |
|---|---|---|---|---|---|
| Total Revenue | 110.6077 | 39.6845 | 31.0053 | 60.5293563 | 52.1182648 |
| Total Expenses | 121.8404 | 53.5932 | 41.6437 | 61.5650796 | 51.1633205 |
| Profit After Tax | -9.6826 | -3.4793 | -11.571 | -0.6104637 | 2.9298518 |
Oxygenta Pharmaceutical Ltd Shareholding Pattern
| Promoter Holdings | 55.934 % |
| FIIs | 0.000 % |
| DIIs | 0.000 % |
| MutualFund | 0.026 % |
| Retail | 38.903 % |
| Others - | 5.137 % |
About Oxygenta Pharmaceutical Ltd
History of Oxygenta Pharmaceutical Ltd
Oxygenta Pharmaceutical Limited was initially incorporated as S S Organics Private Limited as a private limited Company in 1990. The Company converted its status to a Public Limited Company in 1993 changing the name to S S Organics Limited. Further, it was changed to Oxygenta Pharmaceutical Limited in FY 2021-22. The Company was incorporated with the objective of carrying on the business of manufacturing all classes and kinds of Drugs including Pharmaceutical preparation, and Organic Fine Chemicals. It manufactures a wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs. The Company has plant located at Medak in Andhra Pradesh. The Company is strong in manufacturing of anti ulcerative and anti bacterial drugs. The Company is doing contract manufacturing work for APL and also having its own production. Apart from these, it is doing contract manufacturing work with APL for manufacturing of Cirprofloxacin HCL from Q-Acid and has been manufacturing Pantaprozole Sodium and Gabapentine for own production. This contract manufacturing helped the Company to meet major operational expenses. Since the Company started commercial production in July, 2015 after fire accident tragedy, it is in process of stabilizing the manufacturing and marketing. ...
